Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jth.12946 http://scihub22266oqcxt.onion/10.1111/jth.12946 C4501322!4501322!26149050     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Haemost 2015 ; 13 (Suppl 1): S47-53 Nephropedia Template TP {{tp|p=26149050|t=2015. Manipulating megakaryocytes to manufacture platelets ex vivo |pdf=|usr=}}{{26149050}} gab.com Text Manipulating megakaryocytes to manufacture platelets ex vivo JO: J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=26149050 #FOAvip Historically, platelet transfusion has proven a reliable way to treat patients suffering from thrombocytopenia or similar ailments. An undersupply of donors, however, has demanded alternative platelet sources. Scientists have therefore sought to recapitulate the biological events that convert hematopoietic stem cells into platelets in the laboratory. Such platelets have shown good function and potential for treatment. Yet the number manufactured ex vivo falls well short of clinical application. Part of the reason is the remarkable gaps in our understanding of the molecular mechanisms driving platelet formation. Using several stem cell sources, scientists have progressively clarified the chemical signaling and physical microenvironment that optimize ex vivo platelets and reconstituted them in synthetic environments. Key advances in cell reprogramming and the ability to propagate self-renewal have extended the lifetime of megakaryocytes to increase the pool of platelet progenitors. Twit Text FOAVip Manipulating megakaryocytes to manufacture platelets ex vivo ????J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=26149050 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26149050 #FOAvip English Wikipedia <ref>{{Cite pmid|26149050}}</ref> Manipulating megakaryocytes to manufacture platelets ex vivo #MMPMID26149050 Karagiannis P; Eto K J Thromb Haemost 2015[Jun]; 13 (Suppl 1): S47-53 PMID26149050show ga Historically, platelet transfusion has proven a reliable way to treat patients suffering from thrombocytopenia or similar ailments. An undersupply of donors, however, has demanded alternative platelet sources. Scientists have therefore sought to recapitulate the biological events that convert hematopoietic stem cells into platelets in the laboratory. Such platelets have shown good function and potential for treatment. Yet the number manufactured ex vivo falls well short of clinical application. Part of the reason is the remarkable gaps in our understanding of the molecular mechanisms driving platelet formation. Using several stem cell sources, scientists have progressively clarified the chemical signaling and physical microenvironment that optimize ex vivo platelets and reconstituted them in synthetic environments. Key advances in cell reprogramming and the ability to propagate self-renewal have extended the lifetime of megakaryocytes to increase the pool of platelet progenitors. äManipulating megakaryocytes to manufacture platelets ex vivo (epmc).pdf DeepDyve Pubget Overpricing